From an oncology perspective, the big drama played out in advanced high risk prostate cancer at this meeting. There were three new approvals in US last year and approval of some of them in Europe is immiment, including sanofi-aventis’s cabazitazel (Jevtana), which was approved by the EMEA at the EAU conference.

2010 and 2011 are therefore promising to be great years for increased patient and physician choice.

We took a quick look at the new data and what new therapies will likely impact the landscape for this disease in the near term, including abiraterone:

This is my first videoblog but more will be coming, including a snapshot later this week of what’s hot at the AACR meeting next weekend. Do feel free to add any comments below.

Watch this space for more!